

INVITATION TO A LIVE WEBCAST



Why Once Daily Oral Medication is Replacing Twice-Daily Insulin in Feline Diabetes Care

September 29, 2026 at 7 p.m. (EDT)

4:00 5:00 6:00 7:00 8:00 8:30
BC (PDT) AB (MDT) SK/MB (CDT) ON/QC (EDT) PEI/NB/NS (ADT) NL (NDT)



A new era in feline medicine began in 2024 when the first SGLT2 inhibitor for diabetic cats in Canada was introduced (velagliflozin). Now a second SGLT2 inhibitor (bexagliflozin) is finally available. This webinar will build on the experiences of using this drug class in cats to highlight what we have learned and to introduce bexagliflozin, a new option that will improve quality of life for diabetic cats and their owners.

[Click here to sign up NOW!](#)

Or scan this QR code



Susan Little

DVM, DABVP (Feline Practice)

Dr. Susan Little received her Bachelor of Science degree from Dalhousie University (Nova Scotia, Canada) and her DVM from the Ontario Veterinary College, University of Guelph. She has been board certified in Feline Practice since 1997. She is part owner of two feline specialty practices in Ottawa, Canada. She has served on the board of the International Council for Veterinary Assessments, the American Association of Feline Practitioners (now the Feline Veterinary Medical Association), and the Winn Feline Foundation (now the EveryCat Foundation). She is a peer reviewer for veterinary journals as well as the author or co-author of many journal articles. Dr. Little is the recipient of the Canadian Veterinary Medical Association Small Animal Practitioner Award (2010), the NAVC Small Animal Speaker of the Year Award (2013), and the International Society of Feline Medicine/Hill's Pet Nutrition Award for outstanding contributions to feline medicine (2013). She is the editor and co-author of The Cat – Clinical Medicine and Management (2nd edition 2024) and August's Consultations in Feline Internal Medicine, Volume 7.

Following this presentation, we invite you to stay on for an extra 15 minutes to learn more about Bexacat®.



Mel Pinel

DVM, Elanco Veterinary Technical Consultant for Western Canada

Bexacat: The New Sweet Spot in Feline Diabetes Care.

Managing feline diabetes mellitus can present many clinical challenges, including difficulty in achieving consistent glycemic control, the need for significant monitoring, and owner reluctance to administer daily injections. We are excited to invite you to an exclusive webinar hosted by an Elanco Technical Services veterinarian to discuss the latest addition to the SGLT2 inhibitor class: Bexacat® (bexagliflozin tablets).

Brought to you by



Powered by

